GlassScriptPhysician profile
Alvaro Guzman
NPI 1568524668
$2,053.80
in general payments reported to CMS, 2019-2025
23 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $207 · 2021: $306 · 2022: $139 · 2023: $130 · 2024: $56.86 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $384.01 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $207.55 | 2019-2021 | |
| Janssen Biotech, INC. | $202.33 | 2019 | |
| Viiv Healthcare Company | $189.96 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.14 | 2019-2022 | |
| Bausch Health US, LLC | $114.16 | 2021-2022 | |
| Allergan, INC. | $99.05 | 2019-2020 | |
| Indivior INC. | $94.12 | 2019 | |
| Gilead Sciences, INC. | $92.31 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.03 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $61.79 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $60.97 | 2019-2020 | |
| Neos Therapeutics, LP | $32.21 | 2019 | |
| Merck Sharp & Dohme LLC | $26.76 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $21.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.12 | 2021 | |
| Napo Pharmaceuticals INC | $17.75 | 2019 | |
| Shire North American Group INC | $16.25 | 2019 | |
| Axsome Therapeutics, INC. | $16.08 | 2023 | Auvelity |
| Abbvie INC. | $15.57 | 2024 | |
| Avion Pharmaceuticals | $13.57 | 2023 | Methylphenidate Hydrochloride |
| Eisai INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvaro Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.